Entry Point Capital, LLC Tyra Biosciences, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding TYRA
# of Institutions
77Shares Held
43.4MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA10.4MShares$214 Million2.51% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$133 Million5.73% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$96 Million2.28% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$90.8 Million85.38% of portfolio
-
Nextech Invest Ag4.06MShares$83.5 Million12.24% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $864M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...